BIOCRYST PHARMACEUTICALS, INC. Payments to Acquire Available-for-sale Securities
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Payments to Acquire Available-for-sale Securities of $3.67 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2012-05-08
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2012-03-31 was $3.67M, a 18.37% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2011-03-31 was $4.49M.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2011 was $45.50M, a 18.62% decline from fiscal 2010.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2010 was $55.91M, a 3.34% increase from fiscal 2009.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2009 was $54.10M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|
| 2012-03-31 | $3.67M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $45.50M 10-K · filed 2012-03-06 | |
| 2011-03-31 | $4.49M 10-Q · filed 2012-05-08 | |
| 2010-12-31 | $55.91M 10-K · filed 2012-03-06 | |
| 2009-12-31 | $54.10M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |